Dapagliflozin effects on exercise, cardiac remodeling, biomarkers, and renal and pulmonary function in heart failure patients: not as good as expected?
Dapagliflozin 對心衰竭患者運動、心臟重塑、生物標記、腎功能和肺功能的影響:是否不如預期?
Front Cardiovasc Med 2025-04-01
Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety.
心衰竭與2型糖尿病中的Dapagliflozin:療效、心臟及腎臟效果、安全性。
World J Diabetes 2024-08-05
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial.
Dapagliflozin 在心臟射出分數保留的心衰竭運動期間增強動脈和靜脈順應性:來自於心臟射出分數保留的心衰竭中 Dapagliflozin 的心臟和代謝效應試驗的見解。
Circulation 2024-08-05
這項研究探討Dapagliflozin對心臟衰竭且射血分數保留(HFpEF)患者的影響,涉及37名患者,治療持續24週。主要發現包括:運動時收縮壓平均降低18.8 mm Hg,動脈順應性改善,靜脈容量減少,且這些變化與體重減輕有關。整體來看,Dapagliflozin能增強HFpEF患者的血管功能,可能解釋SGLT2抑制劑在此人群中的臨床益處。
PubMedDOI
The effects of SGLT-2 inhibitors on echocardiographic indices and antioxidative properties in patients with heart failure with reduced ejection fraction and diabetes mellitus.
SGLT-2 抑制劑對於心臟射出分數降低及糖尿病患者的超聲心動圖指標和抗氧化特性的影響。
Eur Rev Med Pharmacol Sci 2024-09-04
Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.
心衰竭中的 Dapagliflozin:功能能力、症狀及安全性結果的綜合性統合分析。
Am J Cardiovasc Drugs 2024-09-11
DAPAGLIFLOZIN EFFECTS ON LEFT VENTRICULAR REMODELING AND FILLING PRESSURES IN HEART FAILURE WITH REDUCED EJECTION FRACTION.
DAPAGLIFLOZIN 對於射血分數降低的心臟衰竭左心室重塑及充填壓力的影響。
J Am Soc Echocardiogr 2024-11-03
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.
Dapagliflozin 在不同血流動力學特徵的 HFrEF 患者真實世界人群中的效果:越糟越好。
Cardiovasc Diabetol 2024-11-23
Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.
empagliflozin 對第二型糖尿病合併保留射出分率心衰竭患者之功能容量、左心室充填壓力及心臟儲備的影響:一項隨機對照開放標籤試驗
Cardiovasc Diabetol 2025-05-09
Dapagliflozin enhances systolic and diastolic function in concordance with clinical response in patients with left ventricular dysfunction.
Dapagliflozin 可增強左心室功能不全患者的收縮與舒張功能,並與臨床反應一致。
Eur Rev Med Pharmacol Sci 2025-05-30
Effects of dapagliflozin on the progression of left ventricular dysfunction in type 2 diabetes mellitus: a randomized controlled trial.
Dapagliflozin 對第二型糖尿病患者左心室功能障礙進展的影響:隨機對照試驗
Cardiovasc Diabetol 2025-06-02